<DOC>
	<DOCNO>NCT01805557</DOCNO>
	<brief_summary>The probability achieve CR R-chemotherapy patient fail rituximab contain first line regimen quite low , particular case non GCB profile . The bioCORAL trial suggest ABC subset dismal outcome whichever induction treatment . Thus argue addition new molecule RDHAP regimen could value . Bortezomib appear best candidate set ABC subtypes constitutively express NFkb , target bortezomib . Data literature suggest encouraging activity R-chemo+ bortezomib non GCB-derived DLBCL , although small series . Thus , addition bortezomib justify need circumvent constitutional resistance chemotherapy . Published experience association bortezomib cytarabine also encourage acceptable cumulative toxicity .</brief_summary>
	<brief_title>Phase II Randomized Study With R-DHAP +/- Bortezomib Induction Therapy Relapsed/Refractory Diffuse Large B-cell Lymphoma ( DLBCL ) Patients Eligible Transplantation . BR-DHAP Versus R-DHAP .</brief_title>
	<detailed_description>This prospective , multicenter , two-arm randomized phase II screening trial34 young patient ( 18-65 year ) affect relapsed/refractory Diffuse Large B-cell Lymphoma ( DLBCL ) diagnosis , eligible high-dose therapy . Aim study ass whether addition Bortezomib R-DHAP promise standard R-DHAP , induction therapy high dose chemotherapy ASCT respect response safety . Patients randomize first relapse : ) standard salvage therapy Rituximab association DHAP every 28 day ( R-DHAP ) 4 cycle b ) Bortezomib association regimen ( BR-DHAP ) . In arm induction therapy follow autologous stem cell transplantation , indicate , allogeneic stem cell transplant . A patient consider evaluable possible ass response PET 4 cycle , patient withdraws study PD , completion study treatment . After provide write informed consent , patient evaluate eligibility 21-day screening period . If continue meet eligibility criterion , randomize receive first dose BR-DHAP R-DHAP .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Lymphoma , Large B-Cell , Diffuse</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<criteria>1 . Age 1865 2 . Relapsed/refractory disease receive one line standard chemoimmunotherapy ( RCHOP , GACHOP , RCHOP like ) 3 . Diffuse Large Bcell Lymphoma relapse . Patient rebiopsied prior study entry . If harmful patient , patient enrol archivial tumor sample block first diagnosis available . 4 . No prior Bortezomib therapy 5 . Measurable and/or evaluable disease 6 . Any Ann Arbor stage IPI group relapse 7 . Performance status &lt; 2 accord ECOG scale unless due lymphoma 8 . No Central Nervous System ( CNS ) disease ( meningeal and/or brain involvement lymphoma ) 9 . Adequate hematological count : ANC &gt; 1.5 x 109/L , Hgb &gt; 9 g/dl ( transfusion independent ) , Platelet count &gt; 75 x 109/L ( transfusion independent ) , exception cytopenia due lymphoma bone marrow involvement 10 . HIV negativity , HCV negativity , HBV negativity patient HBcAb + , HBsAg , HBs Ab+/ HBVDNA negativity ( patient Lamivudine prophylaxis mandatory ) 11 . Normal liver function ( ALP , AST , ALT , GGT , conjugate bilirubin total &lt; 2 x ULN ) relate lymphoma 12 . Normal kidney function ( creatinine clearance &gt; 45 ml/min ) 13 . Cardiac ejection fraction &gt; 50 % ( MUGA scan echocardiography ) 14 . Normal lung function 15 . Absence active opportunistic infection 16 . Non peripheral neuropathy active neurological non neoplastic disease CNS 17 . Non major surgical intervention prior 3 month randomization due lymphoma and/or disease lifethreatening compromise chemotherapy treatment 18 . Disease free prior malignancy lymphoma &gt; 3 year exception currently treat squamous cell basal cell carcinoma skin carcinoma situ cervix breast 19 . Life expectancy &gt; 6 month 20 . No psychiatric illness precludes understanding concept trial signing inform consent 21 . Written inform consent 22 . Women must : postmenopausal least 1 year ( must natural menses least 12 month ) surgically sterile ( hysterectomy bilateral oophorectomy , tubal ligation , otherwise incapable pregnancy ) , abstinent ( discretion investigator/per local regulation ) , sexually active , practice highly effective method birth control ( eg , prescription oral contraceptive , contraceptive injection , contraceptive patch , intrauterine device , doublebarrier method ( eg , condom , diaphragm , cervical cap , spermicidal foam , cream , gel , male partner sterilization ) local regulation permit , entry , must agree continue use method contraception throughout study . They must also prepared continue birth control measure least 12 month terminate treatment . 23 . Women childbearing potential must negative serum urine betahuman chorionic gonadotropin ( betahCG ) pregnancy test screen 24 . Men must agree use acceptable method contraception ( female partner list ) duration study . Men must agree use double barrier method birth control donate sperm study 3 month receive last dose study drug . Exclusion criterion : 1 . Diagnosis Lymphoblastic Lymphoma , Burkitt Lymphoma , Non Hodgkin Lymphoma CD20 negative , Mantle Cell Lymphoma , Follicular Lymphoma g IIIIIIaIIIb , Primary Mediastinal Lymphoma 2 . Age &gt; 65 year 3 . Patients ineligible highdose chemotherapy 4 . Performance status &gt; 2 accord ECOG scale due lymphoma 5 . Patient know suspected hypersensitivity intolerance Rituximab 6 . Patient receive experimental drug use experimental medical device within 4 week plan start treatment . Concurrent participation nontreatment study allow , interfere participation study . 7 . CNS disease ( meningeal and/or brain involvement lymphoma ) 8 . History clinically relevant liver renal insufficiency ; significant cardiac , vascular , pulmonary , gastrointestinal , endocrine , neurologic , rheumatologic , hematologic , psychiatric , metabolic disturbance 9 . Uncontrolled diabetes ( receive antidiabetic agent , subject must stable dose least 3 month first dose study drug 10 . Uncontrolled severe cardiovascular disease include myocardial infarction within six month enrollment , New York Heart Association ( NYHA ) Class III IV heart failure , uncontrolled angina , clinically significant pericardial disease , cardiac amyloidosis 11 . Cardiac ejection fraction &lt; 50 % ( MUGA scan echocardiography ) 12 . Creatinine clearance &lt; 45 ml/min 13 . Presence major neurological disorder 14 . HIV positivity , HCV positivity , HBV positivity exception patient HBcAb + , HbsAg , HBs Ab+/ HBVDNA negative 15 . Active opportunistic infection 16 . Major surgical intervention prior 3 month randomization due lymphoma and/or disease lifethreatening compromise chemotherapy treatment 17 . Prior malignancy lymphoma last 3 year exception currently treat squamous cell basal cell carcinoma skin carcinoma situ cervix breast 18 . Life expectancy &lt; 6 month 19 . Any coexist medical psychological condition would preclude participation study compromise ability give inform consent . 20 . If female , patient pregnant breastfeeding .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>Diffuse Large B-cell Lymphoma ( DLBCL )</keyword>
	<keyword>Bortezomib</keyword>
</DOC>